KRN4884对高脂血症大鼠脂质代谢的影响。

Effect of KRN4884 on lipid metabolism in hyperlipidemic rats.

Yokoyama T, Izumi H, Endoh M, Ogawa N, Izawa T, Okada Y

Pharmaceutical Research Laboratory, Kirin Brewery Co. Ltd., Takasaki, Gunma, Japan.

Gen Pharmacol. 1998 Feb;30(2):233-7. doi: 10.1016/s0306-3623(97)00093-1.

Abstract

KRN4884 is a novel pyridinecarboxamidine type potassium channel opener. 2. To determine whether KRN4884 affects lipid metabolism, we investigated its effects on serum lipid levels by using two types of hyperlipidemic rats: genetically hyperlipidemic obese Zucker rats and diet-induced hyperlipidemic rats fed a high fat diet. KRN4884 dose dependently decreased systolic blood pressure in Zucker rats. 3. Oral administration of KRN4884 (1-10 mg/(kg day) for 14 days dose dependently reduced serum triglyceride levels in Zucker rats. The reductions in serum triglyceride were associated with reductions in triglyceride in chylomicron and very low density lipoprotein. 4. KRN4884 produced no change in serum insulin and glucose levels in Zucker rats. 5. KRN4884 exhibited a similar triglyceride lowering effect in diet-induced hyperlipidemic rats. 6. These results suggest that KRN4884 has a beneficial effect on serum triglyceride levels as well as a hypotensive effect.

摘要

KRN4884是一种新型的吡啶甲脒类钾通道开放剂。2. 为了确定KRN4884是否影响脂质代谢，我们使用两种高脂血症大鼠研究了其对血脂水平的影响：遗传性高脂血症肥胖Zucker大鼠和喂食高脂饮食诱导的高脂血症大鼠。KRN4884剂量依赖性地降低了Zucker大鼠的收缩压。3. 口服KRN4884（1 - 10毫克/（千克·天），持续14天）剂量依赖性地降低了Zucker大鼠的血清甘油三酯水平。血清甘油三酯的降低与乳糜微粒和极低密度脂蛋白中甘油三酯的降低有关。4. KRN4884对Zucker大鼠的血清胰岛素和葡萄糖水平没有影响。5. KRN4884在饮食诱导的高脂血症大鼠中表现出类似的降低甘油三酯的作用。6. 这些结果表明，KRN4884对血清甘油三酯水平有有益作用以及具有降压作用。